Details for Patent: 8,642,025
✉ Email this page to a colleague
Which drugs does patent 8,642,025 protect, and when does it expire?
Patent 8,642,025 protects DAKLINZA and is included in one NDA.
This patent has sixty-eight patent family members in thirty-one countries.
Summary for Patent: 8,642,025
| Title: | Hepatitis C virus inhibitors |
| Abstract: | The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. |
| Inventor(s): | Bachand; Carol (Candiac, CA), Belema; Makonen (North Haven, CT), Deon; Daniel H. (Montreal, CA), Good; Andrew C. (Wallingford, CT), Goodrich; Jason (Wallingford, CT), James; Clint A. (Candiac, CA), Lavoie; Rico (Candiac, CA), Lopez; Omar D. (Wallingford, CT), Martel; Alain (Delson, CA), Meanwell; Nicholas A. (East Hampton, CT), Nguyen; Van N. (Middletown, CT), Romine; Jeffrey Lee (Meriden, CT), Ruediger; Edward H. (Greenfield Park, CA), Snyder; Lawrence B. (Killingworth, CT), St. Laurent; Denis R. (Newington, CT), Yang; Fukang (Madison, CT), Langley; David R. (Meriden, CT), Hamann; Lawrence G. (North Grafton, MA) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
| Application Number: | 13/650,374 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,642,025
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-001 | Jul 24, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF INHIBITING HEPATITIS C VIRUS | ⤷ Sign Up | ||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-001 | Jul 24, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY | ⤷ Sign Up | ||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-002 | Jul 24, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF INHIBITING HEPATITIS C VIRUS | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,642,025
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2049522 | ⤷ Sign Up | C300713 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2049522 | ⤷ Sign Up | CA 2015 00003 | Denmark | ⤷ Sign Up |
| European Patent Office | 2049522 | ⤷ Sign Up | C20150003 00128 | Estonia | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
